ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Shares of the Mountain View, Calif.-based biotech firm Vivus nearly doubled last week after an FDA advisory committee recommended approval of its obesity pill Qnexa. In October 2010, FDA rejected Qnexa over concerns about the risk of cardiovascular events and birth defects. Last year, Vivus resubmitted its application for Qnexa, which combines the already approved drugs topiramate and phentermine, to include a postapproval monitoring strategy. FDA still has to give a final decision on the drug, but approval is “pretty much a done deal,” says Cowen & Co. stock analyst Simos Simeonidis.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter